Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
+$0.05 today
- Market cap
- $66.94M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
Volume 0.61M
Average 0.60M
ACRV Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Acrivon Therapeutics, Inc. Common StockNASDAQ: ACRV
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $19.04M (cash outflow) fell 3.2% year over year, ahead of the -7.7% change in trailing-twelve-month net income. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +35.7% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$84.75M (+8.8%) for the fiscal year ending Dec 2026, a step up from the -3.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.04M+0.3% QoQ
- Last fiscal yearDec 2025
- -$77.91M-3.3% YoY
- LTMMar 2026
- -$77.27M-7.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -3.2% | -7.4% | -4.1 pp |
| 1 year | -3.3% | +8.8% | +12.1 pp |
| 3-year CAGR | +35.7% | +3.5% | -32.3 pp |
| 5-year CAGR | -15.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (77.91M) USD
- Year-over-year change
- +3.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (77.91M) | +3.3% |
| FY2024 | 2024-12-31 | (80.56M) | -33.4% |
| FY2023 | 2023-12-31 | (60.39M) | -93.8% |
| FY2022 | 2022-12-31 | (31.17M) | -91.9% |
| FY2021 | 2021-12-31 | (16.24M) | — |
Net Income vs competitors
How ACRV compares with its peers on the latest reported figures
- ACRV's LTM Mar 2026 net income of $77.27M is the 5th largest of the 10 companies compared; the peer median is $70.03M.
- Its year-over-year change of -7.7% is the 7th highest of 10, against a peer median of +8.2%.
- Over three fiscal years its annual growth of +35.7% compares with a peer median of +7.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $104.29M | +8.2% | -6.9% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $103.27M | -65.4% | +96.0% | 2409.4% |
| LTM Mar 2026 | $78.34M | +28.7% | +2.0% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M | -7.7% | +35.7% | — |
| LTM Mar 2026 | $70.03M | +10.4% | +17.8% | 36859.5% | |
| LTM Mar 2026 | $58.88M | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $44.95M | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $39.95M | +162.9% | +13.7% | — | |
| LTM Mar 2026 | $37.1M | +163.8% | — | 14.5% | |
| Peer median (excluding ACRV) | $70.03M | +8.2% | +7.8% | 1885.0% | |
Competitors are the stored peer set for ACRV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.24M) | (31.17M) | (60.39M) | (80.56M) | (77.91M) |
| Depreciation & Amortization | 37K | 364K | 536K | 1.01M | 919K |
| Deferred Income Tax | 0 | 0 | (3.61M) | 0 | 0 |
| Stock-Based Compensation | 497K | 2.19M | 11.62M | 14.29M | 14.72M |
| Change in Working Capital | 328K | (1.53M) | 8.14M | 2.44M | (2.43M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 798K | (245K) | 3.61M | (3.59M) | 1.54M |
| Other Working Capital | (470K) | (1.29M) | 4.53M | 6.02M | (3.96M) |
| Other Non-Cash Items | 1.4M | 33K | 1.06M | (2.85M) | 1.03M |
| Operating Cash Flow | (13.98M) | (30.12M) | (42.64M) | (65.67M) | (63.67M) |
| Capital Expenditures | (238K) | (2.17M) | (1.29M) | (2.77M) | (1.67M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (150.18M) | (56.53M) | (202.93M) | (81.73M) |
| Sales of Investments | 0 | 10.67M | 108.53M | 153.92M | 149.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (238K) | (141.68M) | 50.72M | (51.77M) | 66.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 104.46M | (257K) | 70M | 1K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1K | (2.75M) | (1.3M) | 51.03M | (750K) |
| Financing Cash Flow | 112.22M | 101.71M | (1.55M) | 121.03M | (749K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 98M | (70.08M) | 6.52M | 3.59M | 1.69M |
| Free Cash Flow | (14.22M) | (32.28M) | (43.93M) | (68.44M) | (65.33M) |
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
Intrinsic Alpha fair value
Locked
Current Price
$1.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.